Sawai Draws On Its Strengths Despite Japanese Pressures

Despite the pressures of local price cuts and the impact of the COVID-19 pandemic, Japan’s Sawai Pharmaceutical is holding steady and believes it can differentiate itself from its peers through a combination of research and development expertise, supply-chain stability and a healthy slate of launches, according to company president Kenzo Sawai.

Speaking to Generics Bulletin in an exclusive interview, Sawai observed that the Japanese market had been both bolstered by government policies to increase uptake of generics over recent years at the